Health Canada approves Takeda's LIVTENCITY™ (maribavir) the First and Only Treatment for Adults with Post-Transplant Cytomegalovirus (CMV) infection

TORONTO, Sept. 20, 2022 /CNW/ - Takeda Canada Inc. is pleased to announce that Health Canada has authorized LIVTENCITY™ for the treatment of adults with post-transplant cytomegalovirus ... | September 20, 2022

Related Keywords

Japan ,United States ,Canada ,Toronto ,Ontario ,American ,Canadians ,Canadian ,Shannon Lowe Emery ,El Chaer ,Clin Virol ,Shariq Haider ,Takeda Canada Inc ,Takeda Pharmaceutical Company Limited ,Research Lead Transplant Malignant Id Juravinski Hospital ,World Health Organization ,Cancer Center ,Medicine Mcmaster University Division Of Infectious Disease ,Springer International Publishing ,Health Canada ,Takeda Canada ,Mcmaster University Division ,Infectious Disease ,General Medicine ,Investigator Assigned Treatment ,Stem Cell Transplant ,Solid Organ Transplant ,General Manager ,Pharmaceutical Company Limited ,Rare Genetics ,Plasma Derived Therapies ,Expert Rev ,Current Scientific Evidence ,Hematopoietic Cell ,European Blood ,Marrow Transplantation Textbook ,International Publishing ,Refractory Cytomegalovirus Infection ,Transplant Recipients ,Clin Infect ,Lancet Vol ,Transplantation Infectious Diseases Community ,Clinical Transplantation ,Canada Newswire ,Takeda Pharmaceutical Company Limited Stock Exchange ,News ,Information ,Press Release ,022 ,Us ,Pleased ,O ,Nnounce ,Hat ,Health ,Gas ,Uthorized ,Or ,The ,Treatment ,F ,Adults ,Ith ,Ytomegalovirus 4502 Jp3463000004 ,